Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The degeneration and dysfunction of neurons are key features of neurodegenerative diseases (NDs). Currently, one of the main challenges facing researchers and clinicians is the ability to obtain reliable diagnostic tools that will allow for the diagnosis of NDs as early as possible and the detection of neuronal dysfunction, preferably in the presymptomatic stage. Additionally, better tools for assessing disease progression in this group of disorders are also being sought. The ideal biomarker must have high sensitivity and specificity, be easy to measure, give reproducible results, and reflect the disease progression. Molecular biomarkers include miRNAs and extracellular microvesicles known as exosomes. They may be measured in two extracellular fluids of the highest importance in NDs, i.e., cerebrospinal fluid (CSF) and blood. The aim of the current review is to summarize the pathophysiology of the four most frequent NDs—i.e., Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS)—as well as current progress in the research into miRNAs as biomarkers in these major neurodegenerative diseases. In addition, we discuss the possibility of using miRNA-based therapies in the treatment of neurodegenerative diseases, and present the limitations of this type of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ngolab, J., Trinh, I., Rockenstein, E., Mante, M., Florio, J., Trejo, M., Masliah, D., Adame, A., Masliah, E., & Rissman, R. A. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0445-5 · Cited by 200
RetractedThe biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation
O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00402 · Cited by 5,287
The impact of microRNAs on protein output
Baek, D., Villén, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. (2008) · Nature · doi:10.1038/nature07242 · Cited by 3,592
Widespread changes in protein synthesis induced by microRNAs
Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008) · Nature · doi:10.1038/nature07228 · Cited by 3,429
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726 · cited 1×
“Another pathological hallmark of AD is neuroinflammation, which is linked to oxidative stress, triggered by various molecular compounds released as a result of inflammatory processes in the brain [31].”
BackgroundSempere, L. F., Freemantle, S., Pitha-Rowe, I., Moss, E., Dmitrovsky, E., & Ambros, V. (2004) · Genome Biology · doi:10.1186/gb-2004-5-3-r13 · Cited by 1,578
MicroRNAs Regulate Brain Morphogenesis in Zebrafish
Giraldez, A. J., Cinalli, R. M., Glasner, M. E., Enright, A. J., Thomson, J. M., Baskerville, S., Hammond, S. M., Bartel, D. P., & Schier, A. F. (2005) · Science · doi:10.1126/science.1109020 · Cited by 1,315
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710263105 · Cited by 1,183 · cited 1×
“It has also been suggested that the loss of these specific miRNAs may contribute to the elevation of BACE1 and Aβ levels, leading to the abnormal formation of amyloid plaques in sporadic AD [48,49].”
BackgroundSerum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164
APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037 · cited 6×
“In addition, they analyzed material obtained from a group of LOAD patients, and showed reduced miR451a and miR-605-5p, with no differences in miR-16-5p, compared to healthy controls [68].”
BackgroundInfluentialBiomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Inflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966 · cited 1×
“Moreover, NDs are multifactorial, and may also be associated with neuroinflammation and oxidative stress [2,3].”
BackgroundCurrent Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772 · cited 1×
“These include amyloid plaques—built with Aβ deposits—and tau protein, which accumulates in neurofibrillary tangles [30].”
BackgroundC9orf72-mediated ALS and FTD: multiple pathways to disease
Balendra, R., & Isaacs, A. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0047-2 · Cited by 715
CSF and blood biomarkers for Parkinson's disease
Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., Mollenhauer, B., Blennow, K., & Calabresi, P. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30024-9 · Cited by 673 · cited 1×
“Unfortunately, the measurement of phosphorylated α-synuclein in the blood has several limitations, because erythrocytes are the major source of this protein in the blood [86].”
BackgroundThe Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623
Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
Gui, Y., Liu, H., Zhang, L., Lv, W., & Hu, X. (2015) · Oncotarget · doi:10.18632/oncotarget.6158 · Cited by 552 · cited 8×
“Furthermore, significant changes in miRNAs—specifically miR-29c, miR-136-3p, miR16-2, miR-331-5p, miR-132-5p, and miR-485-5p—were found in exosomes of CSF obtained from AD patients in comparison to healthy controls [67].”
BackgroundResultInfluentialDopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease
Qu, M., Lin, Q., Huang, L., Fu, Y., Wang, L., He, S., Fu, Y., Yang, S., Zhang, Z., Zhang, L., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.035 · Cited by 543
Sex and gender issues in multiple sclerosis
Harbo, H. F., Gold, R., & Tintoré, M. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613488434 · Cited by 529
Alteration of the microRNA network during the progression of Alzheimer's disease
Lau, P., Bossers, K., Janky, R., Salta, E., Frigerio, C. S., Barbash, S., Rothman, R., Sierksma, A. S. R., Thathiah, A., Greenberg, D., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201974 · Cited by 474
Therapeutic advances of miRNAs: A preclinical and clinical update
Chakraborty, C., Sharma, A. R., Sharma, G., & Lee, S.-S. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2020.08.012 · Cited by 402
Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T., Shill, H., Adler, C., Sabbagh, M., Villa, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094839 · Cited by 385 · cited 2×
“detected several miRNAs in blood and CSF obtained from patients with NDs, which had already been described in the brain samples obtained from patients suffering from these diseases [18].”
BackgroundMethodALS Genetics: Gains, Losses, and Implications for Future Therapies
Kim, G., Gautier, O., Tassoni-Tsuchida, E., Ma, X. R., & Gitler, A. D. (2020) · Neuron · doi:10.1016/j.neuron.2020.08.022 · Cited by 370
Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis
Kraemer, B. C., Schuck, T., Wheeler, J. M., Robinson, L. C., Trojanowski, J. Q., Lee, V. M. Y., & Schellenberg, G. D. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0659-0 · Cited by 350
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Blennow, K. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0073-9 · Cited by 295
The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE
Guerreiro, R. J., Gustafson, D. R., & Hardy, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.025 · Cited by 285 · cited 1×
“Furthermore, PSEN1 mutation is responsible for 80% of the cases of EOAD, while PSEN2 mutation is responsible for only about 5% [32,34].”
BackgroundBiomarkers for Parkinson’s Disease: Recent Advancement
Lotankar, S., Prabhavalkar, K. S., & Bhatt, L. K. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0183-5 · Cited by 282 · cited 1×
“Elevated levels of this protein were observed in PD patients, which may reflect ongoing oxidative stress processes [87].”
BackgroundIdentification of blood microRNAs associated to Parkinsońs disease
Margis, R., Margis, R., & Rieder, C. R. M. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.01.023 · Cited by 263
Axonal damage markers in cerebrospinal fluid are increased in ALS
Brettschneider, J., Petzold, A., Süßmuth, S. D., Ludolph, A. C., & Tumani, H. (2006) · Neurology · doi:10.1212/01.wnl.0000203120.85850.54 · Cited by 261
MicroRNAs in Plasma and Cerebrospinal Fluid as Potential Markers for Alzheimer's Disease
Kiko, T., Nakagawa, K., Tsuduki, T., Furukawa, K., Arai, H., & Miyazawa, T. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-130932 · Cited by 256
Why do so many clinical trials of therapies for Alzheimer's disease fail?
Anderson, R. M., Hadjichrysanthou, C., Evans, S., & Wong, M. M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32399-1 · Cited by 228
Adlakha, Y. K., & Saini, N. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-33 · Cited by 213 · cited 1×
“The majority of known miRNAs are expressed in the brain, but only some of them have been found to represent a brain-specific pattern of expression [17].”
BackgroundCirculating miRNAs as Biomarkers for Neurodegenerative Disorders
Grasso, M., Piscopo, P., Confaloni, A., & Denti, M. (2014) · Molecules · doi:10.3390/molecules19056891 · Cited by 208 · cited 7×
“In the late-onset form of the disease, these are the α-synuclein (SNCA) and leucine-rich repeat kinase2 (LRRK2) genes, while in early-onset PD, they are are parkin (PARK2), PTEN-induced putative kinase 1 (PINK1), and oncogene DJ1 (DJ1) [14].”
BackgroundInfluentialInflammation-related plasma and CSF biomarkers for multiple sclerosis
Huang, J., Khademi, M., Fugger, L., Lindhe, Ö., Novakova, L., Axelsson, M., Malmeström, C., Constantinescu, C., Lycke, J., Piehl, F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912839117 · Cited by 194
Hu, Y., Cao, C., Qin, X.-Y., Yu, Y., Yuan, J., Zhao, Y., & Cheng, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-09097-1 · Cited by 183
The Complex Molecular Biology of Amyotrophic Lateral Sclerosis (ALS)
Redler, R. L., & Dokholyan, N. V. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00002-3 · Cited by 172
MicroRNAs in Neurodegenerative Diseases
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2017.04.002 · Cited by 168 · cited 2×
“This has been confirmed in animal model research, in which the disturbed binding of miRNAs resulted in defects in healthy brain development [11,16].”
BackgroundResultMolecular diagnostics of neurodegenerative disorders
Agrawal, M., & Biswas, A. (2015) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2015.00054 · Cited by 164
Tiribuzi, R., Crispoltoni, L., Porcellati, S., Di Lullo, M., Florenzano, F., Pirro, M., Bagaglia, F., Kawarai, T., Zampolini, M., Orlacchio, A., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.003 · Cited by 162 · cited 5×
“Blood cells miR-128 ↑ Reduction in cathepsin D levels in monocytes 34 AD 37 CTRL [54]”
BackgroundInfluentialBriggs, C. E., Wang, Y., Kong, B., Woo, T.-U. W., Iyer, L. K., & Sonntag, K. C. (2015) · Brain Research · doi:10.1016/j.brainres.2015.05.021 · Cited by 113 · cited 5×
“found upregulated expression of miR-132, miR-92a, miR-27a, and miR-148a, while miR-744 and miR-532-5p were found to be downregulated, in brain samples of PD patients [89].”
BackgroundInfluentialBelloy, M. E., Napolioni, V., Han, S. S., Le Guen, Y., Greicius, M. D., & Initiative, F. T. A. D. N. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0414 · Cited by 110
Zhou, Y., Deng, J., Chu, X., Zhao, Y., & Guo, Y. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-181053 · Cited by 71
Down-regulated expression of microRNA-338-5p contributes to neuropathology in Alzheimer’s disease.
Qian, Q., Zhang, J., He, F.-P., Bao, W.-X., Zheng, T.-T., Zhou, D.-M., Pan, H.-Y., Zhang, H., Zhang, X.-Q., He, X., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201801846r · Cited by 70
Gong, X., Huang, M., & Chen, L. (2022) · eneuro · doi:10.1523/eneuro.0393-21.2021 · Cited by 55 · cited 5×
“miR-132-3p ↑ Activation of microglial cells 5 PD 5 CTRL [95]”
BackgroundInfluential
Cited by
Frontotemporal Dementia, Where Do We Stand? A Narrative Review
Antonioni, A., Raho, E. M., Lopriore, P., Pace, A. P., Latino, R. R., Assogna, M., Mancuso, M., Gragnaniello, D., Granieri, E., Pugliatti, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411732 · Cited by 145
Machine learning and digital biomarkers can detect early stages of neurodegenerative diseases
Chudzik, A., Śledzianowski, A., & Przybyszewski, A. W. (2024) · Sensors · doi:10.3390/s24051572 · Cited by 122
“It has shown promise in detecting neuronal dysfunction in the presymptomatic stage of NDs [14].”
BackgroundTanaka, M., Battaglia, S., & Liloia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13051045 · Cited by 24
Metadata
- Authors
- Doroszkiewicz, J., Groblewska, M., & Mroczko, B.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-04-21
- Volume
- 23
- Issue
- 9
- Pages
- 4610
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4224262903
- Cited by
- 82
- References
- 50
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.